Other technologies

Cell Medica has a robust pipeline of cellular immunotherapy products.

In the field of engineered TCRs, we are working with University College London, to develop the Dominant TCR technology to improve the potency of TCR-modified T cells while maintaining the safety profile.

Our product portfolio also includes baltaleucel-T (CMD-003, EBV-specific T cells) for the treatment of lymphomas associated with the Epstein Barr virus.